Clinerion Announces New Partnership with Maxer Consulting
Clinerion today announced a new partnership with Maxer Consulting. Clinerion's Patient Network Explorer will leverage Maxer's extended network of relations in the international healthcare sector to access promising business opportunities and expand Clinerion’s patient coverage into Italy, promoting and delivering clinical trials-related solutions.
The partners' joint mission is to liaise with study sites to increase patient participation in trials to its full potential by offering tools to optimize protocol design, supporting the efficient start-up of local trials, and planning and consistently hitting realistic patient recruitment targets to enable the achievement of total timeline targets.
Maxer will support commercial and non-commercial sponsors in registering their clinical trials, uploading the results of the clinical trials on the public databases (EU and US), anonymizing the clinical data, and editing relevant scientific papers.
Read the full release, here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
